Akebia Therapeutics, Inc. Draws Down $4.1 Million Series B Financing Tranche
1/9/2012 6:20:38 AM
CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia, today announced that it has drawn down a $4.1 million tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.
comments powered by